Drug intelligence / Profile preview

amantadine + imipramine

Development stage
Preclinical
Lead developer
Supernus Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Amantadine + imipramine is a combination of two small molecule drugs—amantadine, an adamantane derivative with dopaminergic and NMDA receptor antagonist properties, and imipramine, a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin. This combination has been studied for its synergistic antidepressant-like effects in preclinical models. Research indicates that co-administration produces stronger antidepressant effects than either drug alone in behavioral tests such as the forced swimming test. Mechanistically, repeated joint administration upregulates dopamine D2 and D3 receptors in the brain, which may underlie their enhanced efficacy on depressive symptoms resistant to standard treatments[1][2][3][4]. Amantadine is also known for its antiviral activity (against influenza A) and use in Parkinson's disease; imipramine is primarily used for depression.

Other names
amantadine and imipramineamantadine plus imipramine
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on amantadine + imipramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amantadine + imipramine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call